APC: New ‘Primer on Compounding Accreditations’ released

FDA doubles down: Tirzepatide is off shortage

...but that doesn't mean the issue is completely settled. read more →
A couple of state updates

Good news from Alabama, but a problem in Massachusetts read more →
Defending GLP-1 compounding

The latest letters APC's been sending to oppose efforts to restrict compounding read more →
Thumbs-up for FDA crackdown

APC was thrilled when the FDA announced it was taking action against illegal online businesses claiming to sell “research-grade” compounds. read more →
A PANS/PANDAS explainer

For your patients: Information about a couple of underdiagnosed pediatric mental health conditions read more →
What, a year?

In the final board chair column of the year, here are our top 7 accomplishments in 2024. read more →
“Simply not a rational approach to regulating an industry”

This week APC offered its final (and pointed) suggestions to the California Board of Pharmacy on their proposed significant – and we would say unjustified – changes to their compounding regulations. read more →
Get a cease and desist letter from Verrica?

APC has heard reports from several pharmacies that have received them — here's what to know. read more →

April 5, 2024

New ‘Primer on Compounding Accreditations’ released

APC is releasing to its Pharmacy/Facility Members this week a Primer on Compounding Accreditations to assist them in determining accreditations they may wish to pursue.

April 5, 2024

Board approves ketamine and office-pay best practices docs

APC’s Board of Directors has authorized two “best practices” documents aimed at helping APC members practice with utmost care and consistency.

April 5, 2024

California requires med errors reporting … eventually

Community pharmacies — defined as any pharmacy that dispenses medication to an outpatient, including both resident and nonresident pharmacies — are now required to report medication errors in California.

April 5, 2024

Call for compounding scholarship applications

Through the generosity of Pharmacists Mutual Insurance Company, the Pharmacy Compounding Foundation is offering up to two (2) pharmacy students a scholarship valued at $2,500.

April 5, 2024

Input needed: FDA’s demonstrably difficult rule

Before APC determines its position and prepares comments to FDA on the proposed rule, we want to hear from you.

April 5, 2024

A cardiologist tells the truth

If you haven’t read it yet, an excellent commentary was published in Medscape this week by a cardiologist and obesity specialist. He pushes back against rampant misinformation around compounded GLP-1s.

March 28, 2024

CC: March 22, 2024

From APC: Damned if we do, damned if we don’t | 22 March 2024

March 28, 2024

Yes, we’re reviewing that ‘demonstrably difficult’ proposed rule

It’s been breathlessly anticipated for months, and this week it finally published: an FDA proposed rule regarding the Demonstrably Difficult to Compound list.

March 28, 2024

10 days left to apply for APC Fellowship

Since the program’s inception in 1997, 162 professionals have been honored as APC Fellows.

March 28, 2024

Wedgewood is APC’s newest Silver-level supporter

Long-time APC supporter Wedgewood Pharmacy, a compounder focused exclusively on animal health, is our newest 2024 Silver-level Corporate Patron.

March 28, 2024

FDA wants to issue guidance docs without public comment

In a draft report and plan for guidance documents released by FDA earlier this year, the agency indicated that it intends to issue guidance documents without a public notice and comment period.

March 28, 2024

Damned if we do, damned if we don’t

Let’s say you’re APC. You get a call from a producer at a major news network saying that their celebrity medical doctor is doing a story on GLP-1 drugs and wants to include compounded GLP-1s in the piece.

March 18, 2024